Literature DB >> 28093651

Infections in intensive care unit adult patients harboring multidrug-resistant Pseudomonas aeruginosa: implications for prevention and therapy.

B Borgatta1,2,3, L Lagunes4, A T Imbiscuso5, M N Larrosa6, M Lujàn7, J Rello4,8,9.   

Abstract

The purpose of this paper was to report the burden and characteristics of infection by multidrug-resistant Pseudomonas aeruginosa (MDR-PA) in clinical samples from intensive care unit (ICU) adults, and to identify predictors. This was a retrospective observational study at four medical-surgical ICUs. The case cohort comprised adults with documented isolation of an MDR-PA strain from a clinical specimen during ICU stay. Multivariate analysis was performed to identify predictors for MDR-PA infection. During the study period, 5667 patients were admitted to the ICU and P. aeruginosa was isolated in 504 (8.8%). MDR-PA was identified in 142 clinical samples from 104 patients (20.6%); 62 (43.6%) of these samples appeared to be true infections. One hundred and eighteen (83.1%) isolates were susceptible only to amikacin and colistin, and 13 (9.2%) were susceptible only to colistin. Overall, the MIC50 to meropenem was 16 μg/mL and the MIC90 was >32 μg/mL, with 60.4% of respiratory samples being MIC >32 μg/mL to meropenem. Independent predictors for MDR-PA infection were fever/hypothermia [odds ratio (OR) 9.09], recent antipseudomonal cephalosporin therapy (OR 6.31), vasopressors at infection onset (OR 4.40), and PIRO (predisposition, infection, response, and organ dysfunction) score >2 (OR 2.06). This study provides novel information that may be of use for the clinical management of patients harboring MDR-PA and for the control of the spread of this organism.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28093651     DOI: 10.1007/s10096-016-2894-3

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  23 in total

1.  Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2005-02-15       Impact factor: 21.405

2.  Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact.

Authors:  Valerie Aloush; Shiri Navon-Venezia; Yardena Seigman-Igra; Shaltiel Cabili; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

3.  The ventilator-associated pneumonia PIRO score: a tool for predicting ICU mortality and health-care resources use in ventilator-associated pneumonia.

Authors:  Thiago Lisboa; Emili Diaz; Marcio Sa-Borges; Antonia Socias; Jordi Sole-Violan; Alejandro Rodríguez; Jordi Rello
Journal:  Chest       Date:  2008-09-08       Impact factor: 9.410

Review 4.  Ventilator-associated tracheobronchitis and pneumonia: thinking outside the box.

Authors:  Donald E Craven; Karin I Hjalmarson
Journal:  Clin Infect Dis       Date:  2010-08-01       Impact factor: 9.079

Review 5.  Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options.

Authors:  Marilee D Obritsch; Douglas N Fish; Robert MacLaren; Rose Jung
Journal:  Pharmacotherapy       Date:  2005-10       Impact factor: 4.705

6.  Risk adjustment in outcome assessment: the Charlson comorbidity index.

Authors:  W D'Hoore; C Sicotte; C Tilquin
Journal:  Methods Inf Med       Date:  1993-11       Impact factor: 2.176

7.  Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine.

Authors:  J L Vincent; A de Mendonça; F Cantraine; R Moreno; J Takala; P M Suter; C L Sprung; F Colardyn; S Blecher
Journal:  Crit Care Med       Date:  1998-11       Impact factor: 7.598

8.  PIRO score for community-acquired pneumonia: a new prediction rule for assessment of severity in intensive care unit patients with community-acquired pneumonia.

Authors:  Jordi Rello; Alejandro Rodriguez; Thiago Lisboa; Miguel Gallego; Manel Lujan; Richard Wunderink
Journal:  Crit Care Med       Date:  2009-02       Impact factor: 7.598

9.  Higher frequency of secretor phenotype in O blood group - its benefits in prevention and/or treatment of some diseases.

Authors:  Mohamad Salih Jaff
Journal:  Int J Nanomedicine       Date:  2010-11-02

10.  An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance.

Authors:  Scott T Micek; Richard G Wunderink; Marin H Kollef; Catherine Chen; Jordi Rello; Jean Chastre; Massimo Antonelli; Tobias Welte; Bernard Clair; Helmut Ostermann; Esther Calbo; Antoni Torres; Francesco Menichetti; Garrett E Schramm; Vandana Menon
Journal:  Crit Care       Date:  2015-05-06       Impact factor: 9.097

View more
  3 in total

1.  The clinical significance of pneumonia in patients with respiratory specimens harbouring multidrug-resistant Pseudomonas aeruginosa: a 5-year retrospective study following 5667 patients in four general ICUs.

Authors:  B Borgatta; S Gattarello; C A Mazo; A T Imbiscuso; M N Larrosa; M Lujàn; J Rello
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-06-17       Impact factor: 3.267

Review 2.  Molecular epidemiology of carbapenem-resistant Pseudomonas aeruginosa in an endemic area: comparison with global data.

Authors:  Theodoros Karampatakis; Charalampos Antachopoulos; Athanassios Tsakris; Emmanuel Roilides
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-04-11       Impact factor: 3.267

3.  Understanding resistance in Pseudomonas.

Authors:  George Dimopoulos; Murat Akova; Jordi Rello; Garyphalia Poulakou
Journal:  Intensive Care Med       Date:  2020-01-20       Impact factor: 17.440

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.